Shuya Li

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial

Shuya Li, Yuesong Pan, Hao Li et al. · The Lancet · 2023 · 294 citations

Medicine, Neurology, Vascular Surgery +7

Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke

Jie Xu, Anxin Wang, Xia Meng et al. · Stroke · 2021 · 235 citations · Full text

Medicine, Neurology, Pharmacology +17

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Scott E. Kasner, Balakumar Swaminathan, Pablo M. Lavados et al. · The Lancet Neurology · 2018 · 178 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Polydatin modulates inflammation by decreasing NF-κB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood–brain barrier permeability for its neuroprotective effect in pMCAO rat brain

Hui Ji, Xiangjian Zhang, Yuanyuan Du et al. · Brain Research Bulletin · 2011 · 124 citations

Life Sciences, Neurobiology, Neuroscience +17

Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study

Shuya Li, Yuesong Pan, Ziran Wang et al. · Stroke and Vascular Neurology · 2021 · 105 citations · Full text

Medicine, Neurology, Pharmacology +17